On July 20, 2020, the United States Food and Drug Administration (FDA) announced a six-month extension of its enforcement discretion policy for certain regenerative medicine products requiring pre-market review due to the COVID-19 pandemic. Included in a final guidance document entitled, “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use,” this extension will give manufacturers additional time to determine whether they need to submit an investigational new drug (IND) or marketing ...
Blog Editors
Recent Updates
- OIG Limits Sign-On Bonuses to In-Home Family Caregivers
- Governing Health AI Development and Adoption: Insights from HHS’s Recently Announced Strategy to Promote AI in Healthcare
- Stranger Things: New FDA Updates Flip Expectations for the Med Tech Industry in 2026 Upside Down
- The DOJ’s Bulk Sensitive Data Rule and Your Obligation to “Know Your Vendor”
- ACCESS Model: CMMI’s New Technology-Enabled Chronic Care Model